Randomised Placebo-Controlled Single Blind Study to Investigate Single Ascending Doses of GNbAC1 in Multiple Sclerosis Patients Followed by Open-label Extension With Repeated Doses of GNbAC1

Trial Profile

Randomised Placebo-Controlled Single Blind Study to Investigate Single Ascending Doses of GNbAC1 in Multiple Sclerosis Patients Followed by Open-label Extension With Repeated Doses of GNbAC1

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Aug 2015

At a glance

  • Drugs GNbAC1 (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors GeNeuro
  • Most Recent Events

    • 03 Sep 2014 Results published in the Media Release.
    • 28 May 2014 Last checked against ClinicalTrials.gov record.
    • 14 Mar 2014 On 4 Nov 2013, GeNeuro reported the trial is completed however, ClinicalTrials.gov record was updated on 27 Jan 2014 to report the status as active, no longer recruiting with an estimated primary completion date of Feb 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top